Acadia Pharmaceuticals Stock Drops After Mid-Stage Trial Failure
Acadia Pharmaceuticals (ACAD) saw its stock fall nearly 8% in premarket trading following a setback in a mid-stage trial for remlifanserin, an experimental treatment targeting hallucinations and delusions linked to Alzheimer’s disease psychosis. The Phase 2 portion of the trial did not meet expectations based on top-line data released by the company. The failure raises concerns about the drug's efficacy or safety profile at this stage in development, potentially delaying further progress toward late-stage trials or regulatory approval. Investors reacted negatively due to the uncertainty surrounding remlifanserin’s future and its potential as a treatment for Alzheimer’s-related psychosis.
Tickers: $ACAD
Topics: Alzheimer's disease drug development psychosis treatment